Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel Versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
crossref(2023)
摘要
Event-free survival per central review and objective response rate in patients ≥70 years
更多查看译文
关键词
Mantle Cell Lymphoma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要